Streetwise Biotech / Pharmaceuticals Articles



Biopharma Receives PDUFA Goal Date for Nonopioid Pain Drug
Source: Streetwise Reports  (7/18/19)
The FDA deemed the firm's submission for analgesic approval complete. More >


Top Pick Status Given to Small-Cap with Pain Drug Candidate
Source: Streetwise Reports  (7/17/19)
The primary reason for the rating—upcoming trial results—is discussed in an Echelon Wealth Partners report. More >


Seattle Genetics Shares Head Higher After Positive Earnings and ADCETRIS Sales Expansion
Source: Streetwise Reports  (7/17/19)
Seattle Genetics announced a 28.3% increase in net sales for its second quarter 2019 powered by ADCETRIS sales along with a promising pipeline. More >


Biopharma's Brain Cancer Therapeutic Compelling, Its Stock Undervalued
Source: Streetwise Reports  (7/16/19)
A description of the asset and its potential are provided in a Dawson James report. More >


Galapagos Agrees to $3.95 Billion, 10-Year Licensing Deal Plus $1.1 Billion Investment from Gilead
Source: Streetwise Reports  (7/15/19)
Galapagos announced that Gilead Sciences has agreed to pay $3.95 billion for a 10-year partnership and licensing deal and will invest an additional $1.1 billion in newly issued shares of the company. More >


Illumina Shares Fall Sharply on Lower Revenue Guidance
Source: Streetwise Reports  (7/12/19)
Illumina Inc. shares traded down more than 15% as the company reported lower preliminary Q2/19 revenues and updated its annual revenue guidance. More >


CVS Declares Quarterly Dividend and Gets a Boost from Relaxed Rebate Policy
Source: Streetwise Reports  (7/11/19)
CVS Healthcare announced a $0.50/share quarterly dividend yesterday and got an added boost today as news spreads regarding easing of federal restrictions on pharmacy rebate plans. More >


Biopharma Starts 'Key Catalyst Period,' H2/19, with Clinical Trial in New Indication
Source: Streetwise Reports  (7/10/19)
A study description and expected data readouts this year are provided in a ROTH Capital Partners report. More >


Coverage Initiated on U.S. Biotech with a 'Potential Best-of-Breed Oncolytic Virus'
Source: Streetwise Reports  (7/10/19)
The investment thesis on this immunotherapies developer is made in an H.C. Wainwright & Co. report. More >


Sangamo and Pfizer Report Positive Results for Hemophilia A Study
Source: Streetwise Reports  (7/8/19)
Sangamo Therapeutics and partner Pfizer reported positive results for phase 1/2 Alta study for hemophilia A at the International Society on Thrombosis and Hemostasis Congress in Melbourne, Australia. More >


Coverage Initiated on Biopharma With 'Low Risk/High Margin Assets'
Source: Streetwise Reports  (7/3/19)
The case is made in a ROTH Capital Partners report for investing in this U.S.-based pharma having multiple shots on goal. More >


Amarin Shares Up Sharply on Increased Revenues and Vascepa's Progress
Source: Streetwise Reports  (7/2/19)
Amarin shares are spiking up today by more than 12% on greater than five times 50-day average volume after the company updated its annual revenue forecast and plans for Vascepa. More >


Daniel Carlson

Bioasis Engages With the FDA: Here's What It Means
Source: Daniel Carlson for Streetwise Reports  (7/2/19)
Daniel Carlson of Tailwinds Research examines the implications of correspondence with the regulatory agency as the company advances its lead candidate addressing brain cancer. More >


Coverage Initiated on Developer of Neurodegenerative Disease Therapeutics
Source: Streetwise Reports  (7/1/19)
An H.C. Wainwright & Co. report presented the investment bank's reasons for its bullish view on this California-based biotech. More >


Biopharma Buys 'Insurance Policy Ahead of First Commercial Launch'
Source: Streetwise Reports  (7/1/19)
The terms of the financial transaction and the potential reasons for it are discussed in a BTIG report. More >


Biotech's Data Well Received at Neurodegenerative Diseases Symposium
Source: Streetwise Reports  (6/28/19)
The company shared findings from its lead clinical program, in Alzheimer's disease. More >


Biopharma Responds to FDA Inquiry Concerning Non-Opioid Pain Reliever
Source: Streetwise Reports  (6/28/19)
The firm believes adequate therapeutic safety and efficacy data exist to support regulatory approval. More >


Dova Pharmaceuticals Shares Increase 35% Overnight with FDA Approval
Source: Streetwise Reports  (6/27/19)
The pharmaceutical stock enjoyed a large boost, thanks largely to FDA approval of its supplemental new drug application for DOPTELET for treatment of chronic immune thrombocytopenia. More >


Strategic Partnership Highlights Global Ambitions for NASH Therapy
Source: Streetwise Reports  (6/26/19)
The deal terms and the partner's attractive attributes are discussed in an H.C. Wainwright & Co. report. More >


Coverage Initiated on 'Solid Platform Company' with Sanofi Partnership
Source: Streetwise Reports  (6/26/19)
The reasons why this biopharma makes a compelling investment are outlined in a ROTH Capital Partners report. More >


Biotech in Neuro Diseases Adds Parkinson's Expert to Scientific Advisory Board
Source: Streetwise Reports  (6/22/19)
The expert brings to the board a deep knowledge of neurodegeneration. More >


Biotech Reports 'Eye-Catching, Topline Results' from RSV Vaccine Study
Source: Streetwise Reports  (6/19/19)
The data and how the asset stacks up to others were covered in a ROTH Capital Partners report. More >


Precision Medicine Firm Announces 'Positive' Data in Lymphoma Study
Source: Streetwise Reports  (6/19/19)
The highlights of the results were presented in an H.C. Wainwright & Co. report. More >


Biopharma Advances Dose Escalation Trial in Alcoholic Hepatitis
Source: Streetwise Reports  (6/19/19)
The company received approval to proceed with the next and final dose level. More >


Interim Results Put Biopharma with Tenbagger Potential 'Back on the Map'
Source: Streetwise Reports  (6/11/19)
A key upcoming catalyst and the impact of recent positive trial results are addressed in a ROTH Capital Partners report. More >


Showing Results: 1 to 25 of 917 Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"TEN announced a takeover offer from Sailfish Royalty."
– James Kwantes, Resource Opportunities
"ABN looks priced right for a move back into our Buy column."
– Brien Lundin, Gold Newsletter (Jefferson Financial)
"We maintain our Market Perform rating on EFR."
– Mark Reichman, Noble Capital Markets